Mundipharma makes moves in biosimilar and inhaler programs

UK-based Mundipharma has made steps towards its goals of becoming a leader in the biosimilars field and in growing its respiratory pipeline, it has announced this week.

The Cambridge-based company announced on Tuesday that it had secured a distribution licence from South Korea’s Celltrion for Truxima, a biosimilar of Roche's (ROG: SIX) blockbuster drug MabThera (rituximab).

This biosimilar received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use last week for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. These are all of the indications of the reference biologic.